FIG Invests in Elitepharm to Integrate AI in Nutraceuticals

Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, as stated in a press release. This move positions FIG as a major shareholder in Elitepharm, a leading French company specializing in the formulation and production of dietary supplements.

The investment aims to leverage AI technology to improve the efficiency and effectiveness of dietary supplement production. Narek Sirakanyan, President and CEO of FIG, highlighted the strategic importance of this investment, noting that France's regulatory environment and technological advancements make it an ideal location for producing dietary supplements.

Elitepharm plans to use this investment to accelerate its commercial and industrial development. The company intends to strengthen its existing facilities, acquire new production sites, and expand its private label portfolio. This expansion is part of a broader strategy to enhance control over the value chain and ensure high-quality production standards.

The partnership between FIG and Elitepharm is based on a shared vision of innovation and industrial excellence, with the goal of establishing Elitepharm as a major player in the European market by 2029.